Skip to main content
SpringerLink
Log in

Urethral Bulking Agents

  • Chapter
  • First Online:
Female Urinary Incontinence

Abstract

Urethral bulking agent (UBA) injection is a technique for treating stress urinary incontinence (SUI) in patients with intrinsic sphincter deficiency. UBAs each have a unique composition and mechanism of action for creating the urethral bulk necessary for effective urethral coaptation to prevent the leakage of urine. UBAs can be synthetic or biologic; synthetic UBAs can further be subdivided into particulate and non-particulate agents. UBAs are injected transurethrally, periurethrally, or through device-guided dispensers; injection can be performed under local or general anesthesia. Adverse treatment-related effects are mostly minor and transient, although rare serious complications have been reported. Subjective and objective cure rates vary between patient populations and the type of UBA used, but many patients ultimately require reinjection for recurrent symptoms. While long-term success rates tend to be lower than other surgical options, UBAs represent an excellent minimally invasive approach in properly selected patients for treating SUI.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. D'Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433–77.

    Article  PubMed  Google Scholar 

  2. Radley SC, Chapple CR, Lee JA. Transurethral implantation of silicone polymer for stress incontinence: evaluation of a porcine model and mechanism of action in vivo. BJU Int. 2000;85(6):646–50.

    Article  CAS  PubMed  Google Scholar 

  3. Wasenda EJ, Kirby AC, Lukacz ES, et al. The female continence mechanism measured by high resolution manometry: urethral bulking versus midurethral sling. Neurourol Urodyn. 2018;37(5):1809–14.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Davis NF, Kheradmand F, Creagh T. Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. Int Urogynecol J. 2013;24(6):913–9.

    Article  PubMed  Google Scholar 

  5. Chapple C, Dmochowski R. Particulate versus non-particulate bulking agents in the treatment of stress urinary incontinence. Res Rep Urol. 2019;11:299–310.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Kirchin V, Page T, Keegan PE, et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2017;7:CD003881.

    PubMed  Google Scholar 

  7. Lose G, Mouritsen L, Nielsen JB. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women. BJU Int. 2006;98(1):100–4.

    Article  CAS  PubMed  Google Scholar 

  8. Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J Urol. 2014;192(3):843–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kocjancic E, Mourad S, Acar O. Complications of urethral bulking therapy for female stress urinary incontinence. Neurourol Urodyn. 2019;38(Suppl 4):S12–20.

    PubMed  Google Scholar 

  10. Elmelund M, Sokol ER, Karram MM, et al. Patient characteristics that may influence the effect of urethral injection therapy for female stress urinary incontinence. J Urol. 2019;202(1):125–31.

    Article  PubMed  Google Scholar 

  11. Itkonen Freitas AM, Mentula M, Rahkola-Soisalo P, et al. Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: a randomized clinical trial. J Urol. 2020;203(2):372–8.

    Article  PubMed  Google Scholar 

  12. Mamut A, Carlson KV. Periurethral bulking agents for female stress urinary incontinence in Canada. Can Urol Assoc J. 2017;11(6Suppl2):S152–S4.

    Google Scholar 

  13. Corcos J, Collet JP, Shapiro S, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology. 2005;65(5):898–904.

    Article  CAS  PubMed  Google Scholar 

  14. Li H, Westney OL. Injection of urethral bulking agents. Urol Clin North Am. 2019;46(1):1–15.

    Article  PubMed  Google Scholar 

  15. Bulkamid standard operating procedure: Contura; Available from: https://bulkamid.com/wp-content/uploads/2019/03/BULK_2018_041.2_SOP_12.04.18.pdf.

  16. Urolastic instructions for use: Urogyn BV; Available from: https://www.urogynbv.com/wp-content/uploads/2015/09/Urolastic-IFU-EN-rev6-06OCT2014.pdf.

  17. Tamanini JT, D'Ancona CA, Tadini V, et al. Macroplastique implantation system for the treatment of female stress urinary incontinence. J Urol. 2003;169(6):2229–33.

    Article  PubMed  Google Scholar 

  18. Dray EV, Hall M, Covalschi D, et al. Can urethral bulking agents salvage failed slings? Urology. 2019;124:78–82.

    Article  PubMed  Google Scholar 

  19. Hegde A, Smith AL, Aguilar VC, et al. Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent. Int Urogynecol J. 2013;24(7):1151–9.

    Article  PubMed  Google Scholar 

  20. Schulz JA, Nager CW, Stanton SL, et al. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(4):261–5.

    PubMed  Google Scholar 

  21. Faerber GJ, Belville WD, Ohl DA, et al. Comparison of transurethral versus periurethral collagen injection in women with intrinsic sphincter deficiency. Tech Urol. 1998;4(3):124–7.

    CAS  PubMed  Google Scholar 

  22. Gaines N, Gupta P, Khourdaji AS, et al. Radiographic misdiagnoses after Periurethral bulking agents. Female Pelvic Med Reconstr Surg. 2018;24(4):312–4.

    Article  PubMed  Google Scholar 

  23. Hussain SM, Bray R. Urethral bulking agents for female stress urinary incontinence. Neurourol Urodyn. 2019;38(3):887–92.

    Article  CAS  PubMed  Google Scholar 

  24. Murless BC. The injection treatment of stress incontinence. J Obstet Gynaecol Br Emp. 1938;45:67–73.

    Google Scholar 

  25. Sachse H. Treatment of urinary incontinence with sclerosing solutions. Indications, results, complications. Urol Int. 1963;15:225–44.

    Article  CAS  PubMed  Google Scholar 

  26. Taylor AK, Dielubanza E, Hairston J. Use of injectable urethral bulking agents in the management of stress urinary incontinence. Curr Bladder Dysfunct Rep. 2011;6:159(2011).

    Article  Google Scholar 

  27. Politano VA. Periurethral polytetrafluoroethylene injection for urinary incontinence. J Urol. 1982;127(3):439–42.

    Article  CAS  PubMed  Google Scholar 

  28. Malizia AA Jr, Reiman HM, Myers RP, et al. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). JAMA. 1984;251(24):3277–81.

    Article  PubMed  Google Scholar 

  29. Kiilholma PJ, Chancellor MB, Makinen J, et al. Complications of Teflon injection for stress urinary incontinence. Neurourol Urodyn. 1993;12(2):131–7.

    Article  CAS  PubMed  Google Scholar 

  30. Santiago Gonzalez de Garibay AM, Castro Morrondo J, Castillo Jimeno JM, et al. Endoscopic injection of autologous adipose tissue in the treatment of female incontinence. Arch Esp Urol. 1989;42(2):143–6.

    Google Scholar 

  31. Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. J Urol. 2001;165(1):153–8.

    Article  CAS  PubMed  Google Scholar 

  32. Horl HW, Feller AM, Biemer E. Technique for liposuction fat reimplantation and long-term volume evaluation by magnetic resonance imaging. Ann Plast Surg. 1991;26(3):248–58.

    Article  CAS  PubMed  Google Scholar 

  33. Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;56(6 Suppl 1):32–40.

    Article  CAS  PubMed  Google Scholar 

  34. Winters JC, Appell R. Periurethral injection of collagen in the treatment of intrinsic sphincteric deficiency in the female patient. Urol Clin North Am. 1995;22(3):673–8.

    Article  CAS  PubMed  Google Scholar 

  35. Sweat SD, Lightner DJ. Complications of sterile abscess formation and pulmonary embolism following periurethral bulking agents. J Urol. 1999;161(1):93–6.

    Article  CAS  PubMed  Google Scholar 

  36. Mukkamala A, Latini JM, Cameron AP. Urethrocutaneous fistula after use of Tegress bulking agent: case report and review of the literature. Can Urol Assoc J. 2013;7(11-12):E833–6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Dmochowski RR. Tegresstrade mark urethral implant phase III clinical experience and product uniqueness. Rev Urol. 2005;7(Suppl 1):S22–6.

    PubMed  PubMed Central  Google Scholar 

  38. Hurtado EA, Appell RA. Complications of Tegress injections. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(1):127; author reply 9.

    Article  Google Scholar 

  39. Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. Eur Urol. 2005;48(3):488–94.

    Article  CAS  PubMed  Google Scholar 

  40. Lightner D, Rovner E, Corcos J, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology. 2009;74(4):771–5.

    Article  PubMed  Google Scholar 

  41. Permacol(TM) Surgical implant: Medtronic; 2020. Available from: https://www.medtronic.com/covidien/en-us/products/hernia-repair/permacol-surgical-implant.html.

  42. Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(2):147–50; discussion 50.

    Article  CAS  PubMed  Google Scholar 

  43. Mayer RD, Dmochowski RR, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007;69(5):876–80.

    Article  CAS  PubMed  Google Scholar 

  44. Unger CA, Barber MD, Walters MD. Ultrasound evaluation of the urethra and bladder neck before and after transurethral bulking. Female Pelvic Med Reconstr Surg. 2016;22(2):118–22.

    Article  PubMed  Google Scholar 

  45. Lai HH, Hurtado EA, Appell RA. Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1315–7.

    Article  PubMed  Google Scholar 

  46. Palma PC, Riccetto CL, Martins MH, et al. Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):670–1.

    Article  PubMed  Google Scholar 

  47. Summary of safety and effectiveness data: Durasphere(TM) Injectable Bulking Agent: United States Food and Drug Administration; 1999. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/P980053b.pdf.

  48. Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology. 2001;58(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  49. Chrouser KL, Fick F, Goel A, et al. Carbon coated zirconium beads in beta-glucan gel and bovine glutaraldehyde cross-linked collagen injections for intrinsic sphincter deficiency: continence and satisfaction after extended followup. J Urol. 2004;171(3):1152–5.

    Article  CAS  PubMed  Google Scholar 

  50. Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol. 2001;166(4):1350–3.

    Article  CAS  PubMed  Google Scholar 

  51. Ghoniem GM, Khater U. Urethral prolapse after durasphere injection. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(3):297–8.

    Article  PubMed  Google Scholar 

  52. Sokol ER, Aguilar VC, Sung VW, et al. Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(5):643–7.

    Article  PubMed  Google Scholar 

  53. Ghoniem G, Corcos J, Comiter C, et al. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183(4):1444–9.

    Article  PubMed  Google Scholar 

  54. Ghoniem G, Corcos J, Comiter C, et al. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol. 2009;181(1):204–10.

    Article  PubMed  Google Scholar 

  55. Ghoniem GM, Miller CJ. A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J. 2013;24(1):27–36.

    Article  PubMed  Google Scholar 

  56. Bennett AT, Lukacz ES. Two cases of suspected rejection of polydimethylsiloxane urethral bulking agent. Female Pelvic Med Reconstr Surg. 2017;23(3):e10–e1.

    Article  PubMed  Google Scholar 

  57. Kulkarni S, Davies AJ, Treurnicht K, et al. Misplaced Macroplastique injection presenting as a vaginal nodule and a bladder mass. Int J Clin Pract Suppl. 2005;(147):85–6.

    Google Scholar 

  58. Rodriguez D, Jaffer A, Hilmy M, et al. Bladder neck and urethral erosions after Macroplastique injections. Low Urin Tract Symptoms. 2020;13:93.

    Article  PubMed  Google Scholar 

  59. Thompson A, Daborn JP. A vaginal mass and ulceration 8 years following Macroplastique(R) injection. Int Urogynecol J. 2015;26(10):1547–8.

    Article  PubMed  Google Scholar 

  60. Wasenda EJ, Nager CW. Suburethral mass formation after injection of polydimethylsiloxane (Macroplastique(R)) urethral bulking agent. Int Urogynecol J. 2016;27(12):1935–6.

    Article  PubMed  Google Scholar 

  61. Serati M, Soligo M, Braga A, et al. Efficacy and safety of polydimethylsiloxane injection (Macroplastique((R)) ) for the treatment of female stress urinary incontinence: results of a series of 85 patients with >/=3 years of follow-up. BJU Int. 2019;123(2):353–9.

    Article  CAS  PubMed  Google Scholar 

  62. Tamanini JT, D'Ancona CA, Netto NR Jr. Treatment of intrinsic sphincter deficiency using the Macroplastique implantation system: two-year follow-up. J Endourol. 2004;18(9):906–11.

    Article  PubMed  Google Scholar 

  63. Tamanini JT, D'Ancona CA, Netto NR. Macroplastique implantation system for female stress urinary incontinence: long-term follow-up. J Endourol. 2006;20(12):1082–6.

    Article  PubMed  Google Scholar 

  64. Plotti F, Zullo MA, Sansone M, et al. Post radical hysterectomy urinary incontinence: a prospective study of transurethral bulking agents injection. Gynecol Oncol. 2009;112(1):90–4.

    Article  PubMed  Google Scholar 

  65. Christensen LH, Nielsen JB, Mouritsen L, et al. Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig. Dermatol Surg. 2008;34 Suppl 1:S68–77; discussion S.

    Google Scholar 

  66. Zivanovic I, Rautenberg O, Lobodasch K, et al. Urethral bulking for recurrent stress urinary incontinence after midurethral sling failure. Neurourol Urodyn. 2017;36(3):722–6.

    Article  CAS  PubMed  Google Scholar 

  67. Kasi AD, Pergialiotis V, Perrea DN, et al. Polyacrylamide hydrogel (Bulkamid(R)) for stress urinary incontinence in women: a systematic review of the literature. Int Urogynecol J. 2016;27(3):367–75.

    Article  PubMed  Google Scholar 

  68. Gopinath D, Smith AR, Reid FM. Periurethral abscess following polyacrylamide hydrogel (Bulkamid) for stress urinary incontinence. Int Urogynecol J. 2012;23(11):1645–8.

    Article  CAS  PubMed  Google Scholar 

  69. Martan A, Masata J, Svabik K, et al. Transurethral injection of polyacrylamide hydrogel (Bulkamid((R))) for the treatment of female stress or mixed urinary incontinence. Eur J Obstet Gynecol Reprod Biol. 2014;178:199–202.

    Article  CAS  PubMed  Google Scholar 

  70. Leone Roberti Maggiore U, Alessandri F, Medica M, et al. Periurethral injection of polyacrylamide hydrogel for the treatment of stress urinary incontinence: the impact on female sexual function. J Sex Med. 2012;9(12):3255–63.

    Article  PubMed  Google Scholar 

  71. Krhut J, Martan A, Jurakova M, et al. Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up. Int Urogynecol J. 2016;27(2):301–5.

    Article  PubMed  Google Scholar 

  72. Vecchioli-Scaldazza CV, Smaali C, Morosetti C, et al. Polyacrylamide hydrogel (bulkamid(R)) in female patients of 80 or more years with urinary incontinence. Int Braz J Urol. 2014;40(1):37–43.

    Article  PubMed  Google Scholar 

  73. Kowalik CR, Casteleijn FM, van Eijndhoven HWF, et al. Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery. Neurourol Urodyn. 2018;37(1):339–45.

    Article  PubMed  Google Scholar 

  74. Zajda J, Farag F. Urolastic-a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. Adv Urol. 2013;2013:724082.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Futyma K, Miotla P, Galczynski K, et al. An open multicenter study of clinical efficacy and safety of Urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. Biomed Res Int. 2015;2015:851823.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Futyma K, Nowakowski L, Galczynski K, et al. Nonabsorbable urethral bulking agent - clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. Eur J Obstet Gynecol Reprod Biol. 2016;207:68–72.

    Article  PubMed  Google Scholar 

  77. Zajda J, Farag F. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up. Cent Eur J Urol. 2015;68(3):334–8.

    Article  Google Scholar 

  78. Capobianco G, Azzena A, Saderi L, et al. Urolastic(R), a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis. Int Urogynecol J. 2018;29(9):1239–47.

    Article  PubMed  Google Scholar 

  79. Casteleijn FM, Kowalik CR, Berends C, et al. Patients' satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: a cross-sectional study. Neurourol Urodyn. 2020;39(6):1753–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Kobashi KC, Albo ME, Dmochowski RR, et al. Surgical treatment of female stress urinary incontinence: AUA/SUFU guideline. J Urol. 2017;198(4):875–83.

    Article  PubMed  Google Scholar 

  81. Burkhard FC, Bosch, JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A, Ambühl D, Bedretdinova DA, Farag F, Lombardo R, Schneider MP. Urinary incontinence 2018. Available from: https://uroweb.org/guideline/urinary-incontinence/.

  82. Leone Roberti Maggiore U, Bogani G, Meschia M, et al. Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2015;189:48–54.

    Article  PubMed  Google Scholar 

  83. Itkonen Freitas AM, Mikkola TS, Rahkola-Soisalo P, et al. Quality of life and sexual function after TVT surgery versus Bulkamid injection for primary stress urinary incontinence: 1 year results from a randomized clinical trial. Int Urogynecol J. 2020;32:595.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Casteleijn FM, Enklaar RA, El Bouyahyaoui I, et al. How cure rates drive patients' preference for urethral bulking agent or mid-urethral sling surgery as therapy for stress urinary incontinence. Neurourol Urodyn. 2019;38(5):1384–91.

    Article  PubMed  Google Scholar 

  85. Giarenis I, Thiagamoorthy G, Zacche M, et al. Management of recurrent stress urinary incontinence after failed midurethral sling: a survey of members of the International Urogynecological Association (IUGA). Int Urogynecol J. 2015;26(9):1285–91.

    Article  PubMed  Google Scholar 

  86. Lee HN, Lee YS, Han JY, et al. Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures. Int Urogynecol J. 2010;21(12):1479–83.

    Article  PubMed  Google Scholar 

  87. Clark R, Welk B. The use of polyacrylamide hydrogel in the setting of failed female stress incontinence surgery. Can Urol Assoc J. 2018;12(4):95–7.

    Article  PubMed  Google Scholar 

  88. Gaddi A, Guaderrama N, Bassiouni N, et al. Repeat midurethral sling compared with urethral bulking for recurrent stress urinary incontinence. Obstet Gynecol. 2014;123(6):1207–12.

    Article  PubMed  Google Scholar 

  89. Rodriguez D, Carroll T, Alhalabi F, et al. Outcomes of Macroplastique injections for stress urinary incontinence after suburethral sling removal. Neurourol Urodyn. 2020;39(3):994–1001.

    Article  CAS  PubMed  Google Scholar 

  90. Macroplastique® Implantation System (MIS): Cogentix Medical; 2021. Available from: https://www.cogentixmedical.com/health-care-professionals/products/macroplastique/implantation-system.

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Alexandra L. Tabakin

  2. Hunterdon Urological Associates, Flemington, NJ, USA

    Siobhan M. Hartigan

Authors
  1. Alexandra L. Tabakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siobhan M. Hartigan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siobhan M. Hartigan .

Editor information

Editors and Affiliations

  1. Urology, University of Michigan, Ann Arbor, MI, USA

    Anne P. Cameron

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tabakin, A.L., Hartigan, S.M. (2022). Urethral Bulking Agents. In: Cameron, A.P. (eds) Female Urinary Incontinence. Springer, Cham. https://doi.org/10.1007/978-3-030-84352-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84352-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84351-9

  • Online ISBN: 978-3-030-84352-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation